

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, Washington, D.C. 20231, on



*3/20/02*

Date of Deposit

Paul E. Rauch, Ph.D.  
Name of Applicant, Assignee or  
Registered Representative

Signature

*3/19/02*

Date of Signature

**RECEIVED**

APR 01 2002

TECH CENTER 1600/2900

Our Case No.: 10466/73

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Ashkenazi et al.

Serial No.: 09/902,853

Filing Date: July 10, 2001

For: SECRETED AND  
TRANSMEMBRANE  
POLYPEPTIDES AND NUCLEIC  
ACIDS ENCODING THE SAME

Examiner: To be assigned

Group Art Unit No.: 1645

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and

made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

**OTHER ART**


1. Blast Results A1-A14, GenBank
2. Blast Results, B1-B4, Dayhoff

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b):

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



---


Paul E. Rauch, Ph.D.  
Registration No. 38,591  
Attorney for Applicant(s)

BRINKS HOFER GILSON & LIONE  
P.O. Box 10395  
Chicago, IL 60610  
(312) 321-4200

**INSTRUCTIONS**

**This Information Disclosure Statement (IDS) is sent in with the PTO form**

**1449. If this is a first IDS in a file, refer to it throughout as "Information Disclosure Statement." If this is an IDS subsequent to the first IDS in a file, refer to it throughout as "First Supplemental Information Disclosure Statement," "Second Supplemental Information Disclosure Statement," "Third Supplemental Information Disclosure Statement," etc. Also, on the Form PTO-1449, Label references with a Prefix "A" for the first filed IDS, "B" for the First Supplemental IDS, "C" for the Second Supplemental IDS, "D" for the Third Supplemental IDS, etc.**



FORM PTO-1449 <i>U.S. TRADEMARK OFFICE</i>	SERIAL NO. 09/902,853	CASE NO. 10466/73
<b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>	FILING DATE July 10, 2001	GROUP ART UNIT 1645
(use several sheets if necessary)	APPLICANT(S): Ashkenazi et al.	

## **REFERENCE DESIGNATION**

## **U.S. PATENT DOCUMENTS**

**RECEIVED**

APR 01 2002

~~TECH CENTER 1600/2900~~

## **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
A1	Blast Results	A1-A14, GenBank
A2	Blast Results,	B1-B4, Dayhoff

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.